このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Project HOPE (Hypertension Outreach Through Partnership and Engagement) (HOPE)

2026年9月3日 更新者:Johns Hopkins University

The goal of this study is to learn if a nurse-led, task-shifting, community-based program can help lower blood pressure in adults aged 25 and older with uncontrolled high blood pressure (hypertension) in Monrovia, Liberia. The program is delivered through community-based mobile clinics by community health nurses (CHNs) trained in WHO-aligned hypertension care within the Ministry of Health's (MOH) Community Health hypertension management protocols.

Participants will:

  • Receive blood pressure treatment from trained community health nurses (CHNs) at community-based mobile clinics in their communities, including medication and lifestyle counseling.
  • Complete surveys at their first visit, at 4 to 6 weeks, and at 3 months about their experience, satisfaction, and medication use.
  • Attend follow-up visits at the mobile clinic based on their blood pressure levels.

Community health nurses delivering the program will complete structured training and be invited to complete surveys before and after training, and to take part in interviews about their experience at the end of the study.

The study will take place over 7 months in five high-thoroughfare communities in Monrovia, Liberia, and aims to enroll 150 participants.

調査の概要

状態

まだ募集していません

詳細な説明

This pilot uses a quasi-experimental, hybrid type 1 effectiveness-implementation design to assess both the clinical effectiveness and implementation outcomes of a nurse-led, community-based hypertension intervention in an urban Liberian setting. The intervention is embedded within the Ministry of Health's (MOH) National Community Health Strategy 2023-2032 and operationalizes the MOH's new Community Health hypertension management protocols, which adapt WHO pharmacologic and non-pharmacologic guidelines to the local context.

Care is delivered by community health nurses (CHNs) operating out of community-based mobile clinics (CBMCs) sited in five contiguous, high-thoroughfare communities (Zubah Town, King Gray, Barchue, Kpelle Town, and Congo Town Back Rd). The communities are within 15-20 minutes of each other to support shared logistics and continuity of care across mobile clinic visits. Recruitment occurs over the first 3 months of the 7-month pilot period; each enrolled participant is then followed for 3 months.

CHNs complete a multi-day, competency-based training program led by the Johns Hopkins Center for Health Equity (JHCHE) in partnership with the Liberian implementation team. Training covers standardized BP measurement using a "screen and confirm" protocol (including a 5-minute pre-measurement rest and automated triplicate readings), WHO-aligned pharmacologic step-up algorithm adapted to local formulary and context, and structured non-pharmacologic counseling using a patient-facing Options Tool adapted from the RICH LIFE trial (covering diet, physical activity, smoking cessation, adherence support, danger-sign recognition, and social drivers of hypertension). Motivational interviewing techniques and simplified treatment protocols under physician oversight follow the Addressing Hypertension Care in Africa (ADHINCRA) model. Ongoing technical assistance and remote protocol-fidelity monitoring are provided by the JHCHE team.

The study is being conducted under a dual-Institutional Review Board (IRB) structure: the Liberian team holds local IRB approval for the patient-care component, while Johns Hopkins Medicine (JHM) IRB approval covers all CHN-facing research activities and a secondary evaluation of patient outcomes using the limited data set. The work is intended to generate real-world evidence to inform scale-up of equitable, nurse-led chronic disease care across urban and peri-urban communities in Liberia and comparable health systems.

研究の種類

観察的

入学 (推定)

150

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Montserrado County
      • Monrovia、Montserrado County、リベリア
        • Wellness Partners Clinic
        • コンタクト:
        • コンタクト:
          • Cooper
        • 主任研究者:
          • Nicole Cooper, MD, MPH

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

サンプリング方法

非確率サンプル

調査対象母集団

Adults aged 25 years and older with Stage 2 hypertension residing in five high-thoroughfare, underserved communities in Monrovia, Liberia (Zubah Town, King Gray, Barchue, Kpelle Town, and Congo Town Back Road), identified and enrolled through community-based mobile clinics (CBMCs) staffed by community health nurses (CHNs) delivering WHO-aligned hypertension treatment within the Ministry of Health's Community Health hypertension management protocols. Target enrollment is 150 patient participants. CHNs directly involved in intervention delivery are also included for pre/post-training surveys and semi-structured interviews.

説明

Patient Participant Inclusion Criteria:

  • Adults aged ≥25 years
  • Stage 2 hypertension defined as either:

    • Systolic Blood Pressure (SBP) ≥160 mmHg at screening (Group A); OR
    • SBP 140-159 mmHg at screening with either documented elevation on more than one visit or a known history of hypertension (e.g., prior clinician diagnosis or current use of antihypertensive medication) (Group B)

Patient Participant Exclusion Criteria:

  • <25 years of age
  • Hypertensive emergency with SBP ≥180 mmHg at screening (these patients will be referred to the nearest health center per local protocol; they may be re-screened for eligibility at a subsequent visit if SBP meets the inclusion criteria above)
  • Diagnosis of end-stage renal disease (ESRD)
  • Condition which interferes with outcome measurement (e.g., dialysis)
  • Serious medical condition which either limits life expectancy or requires active management (e.g., certain cancers)
  • Cognitive impairment or other condition preventing participation in the intervention
  • Active alcohol or substance use disorder (i.e., not sober/abstinent for ≥30 days), screened using the NIAAA Single Alcohol Screening Question
  • Pregnant or planning pregnancy in the next 24 months
  • Currently nursing a child
  • Current participation in another research study focused on reducing blood pressure
  • Current participation in a care management program related to health conditions (e.g., weight reduction, smoking cessation)
  • Planning to move out of the geographic area within 7 months
  • Unwillingness to provide informed consent

Community Health Nurse (CHN) Participant Inclusion Criteria:

  • CHNs who were directly involved in delivering the nurse-led community-based hypertension intervention
  • Willing to provide oral informed consent for participation in pre/post-training surveys and semi-structured interviews

Community Health Nurse (CHN) Participant Exclusion Criteria:

  • CHNs who were not directly involved in the delivery of the intervention

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

コホートと介入

グループ/コホート
介入・治療
Nurse-Led Community-Based Hypertension Care Cohort
The source population will be community residents living in high thoroughfare areas within five communities (Zubah Town, King Gray, Barchue, Kpelle Town and Congo Town Back Rd) in Monrovia, Liberia. The designated communities are within 15-20 minutes of each other. Patients can receive care at a neighboring site if they miss the day of the week when the clinic is set up in their neighborhood. Patients and community health promoters will have a schedule for all five days that the mobile clinic will move through these communities.

Patients will receive nurse-led treatment for uncontrolled hypertension that includes:

A. Pharmacological treatment in line with the MOH's non-communicable disease protocols and World Health Organization (WHO) Guidelines for the pharmacological treatment of hypertension in adults 1. Medications include calcium channel blockers, thiazide diuretics, angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs).

B. Non-pharmacological treatment including education and counseling on lifestyle interventions (healthy diet, exercise, active non-sedentary lifestyle +/- smoking cessation as needed), medication adherence, danger signs and social factors contributing to hypertension.

The mobile clinics will be in the same community at a specific day of the week, each week, enabling patients to come back for a follow-up on the same day during a future week (either next week or after 4-6 weeks, based on blood pressure readings)

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Change in Systolic Blood Pressure
時間枠:Baseline to 6 months

Within subject change from baseline in systolic blood pressure at the last measurement will be calculated. We will report the mean (95% confidence interval (CI)) in the change. A reduction in systolic blood pressure of ≥ 5 mmHg will be considered clinically significant.

A ≥5 mmHg reduction would be considered clinically meaningful/significant but this will not stop medication titration. Patients showing improvement but still uncontrolled will continue escalation per protocol.

Baseline to 6 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Participants with Controlled Blood Pressure
時間枠:Baseline to 6 months
The percent and exact binomial 95% CI of participants with controlled blood pressure (systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg) at their last visit will be calculated.
Baseline to 6 months
Adherence (Percentage of Participants)
時間枠:Baseline to 6 months

Medication adherence will be measured at the last visit using a self-report measure of the extent of medical nonadherence by Voils which included three questions:

A. I took all doses of my blood pressure medication. B. I missed or skipped at least one dose of my blood pressure medication. C. I was not able to take all of my blood pressure medication. If the participant reports being non-adherent on any of the three adherence yes/no questions, the participant will be coded as non-adherent. If they report being adherent on all three questions they will be coded as adherent. The percent and exact binomial 95% CI for adherent will be reported.

Baseline to 6 months
Adherence (Proportion of medication days missed)
時間枠:Baseline to 6 months
Thee proportion of days (out of 7) that the participant missed taking medications using a single-item self-report medication adherence question and report the mean proportion and 95% CI will be reported.
Baseline to 6 months
Acceptability as assessed by the Theoretical Framework of Acceptability
時間枠:Baseline to 6 months
The investigators will measure four constructs: (a) affective attitude, (b) burden, (c) perceived effectiveness, and (d) opportunity costs, and the (e) overall acceptability rating from the theoretical framework of acceptability (TFA). Items (a) and (b) will be scored such that a score of 1 represents the least desirable response and a score of 5 represents the most desirable response. Items (c), (d) and (e) will have yes/no responses. A composite/summary measure will be created by dichotomizing the 5-point items (Yes = 4 and 5 vs No =1, 2, and 3). Then, a sum of the number of positive responses on the 5 items will be created. A score of 4 on this composite/summary measure (score range: 0-5, higher score better) would be considered ≥ 80% acceptability and would be considered a success at the last visit.
Baseline to 6 months
Satisfaction and Trust
時間枠:Baseline to 6 months
The investigators will measure participant satisfaction and trust using the single item questions. The mean and 95% CI of the responses will be reported. A score of ≥ 4.0 will indicate satisfaction or trust, respectively. These questions are scored using a Likert's scale (score range: 1-5, higher score better) with the following options and scores: Strongly Disagree (1), Disagree (2), Neither Agree nor Disagree (3), Agree (4) Strongly Agree (5)
Baseline to 6 months
Study Completion
時間枠:Baseline to 6 months
The proportion and 95% CI of the participants who did not complete the study will be reported. If available, reasons for withdrawal will also be reported.
Baseline to 6 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Lisa A Cooper, MD, MPH、Johns Hopkins University
  • 主任研究者:Nicole Cooper, MD, MPH、Wellness Partners Clinic

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2027年2月1日

一次修了 (推定)

2027年9月30日

研究の完了 (推定)

2027年9月30日

試験登録日

最初に提出

2026年6月26日

QC基準を満たした最初の提出物

2026年6月26日

最初の投稿 (実際)

2026年7月2日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月8日

QC基準を満たした最後の更新が送信されました

2026年9月3日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する